Discovery of anticonvulsant activity of abietic acid through application of linear discriminant analysis

Bioorganic and Medicinal Chemistry Letters

Volumn 17, Issue 6, 2007, Pages 1684-1690

  Talevi, Alan ^a,b   Cravero, Mariana Sella ^b   Castro, Eduardo A ^a   Bruno Blanch, Luis E ^b  

^a INSTITUTO DE INVESTIGACIONES FISICOQUÍMICAS TEÓRICAS Y APLICADAS INIFTA   (Argentina)

^b FACULTAD DE CIENCIAS EXACTAS   (Argentina)

Author keywords

Abietic acid; Anticonvulsant; Epilepsy; Linear discriminant analysis

Indexed keywords

ABACAVIR; ABIETIC ACID; ACEBUTOLOL; ALCLOFENAC; AMPRENAVIR; ANTICONVULSIVE AGENT; ATEVIRDINE; BIAPENEM; CANDESARTAN; CANNABIDIOL; CEFALEXIN; CLINDAMYCIN; CLONAZEPAM; DELAPRIL; DIAZEPAM; DIHYDROCODEINE; ENALAPRIL; FELBAMATE; HARKOSERIDE; LAMOTRIGINE; LANSOPRAZOLE; MISOPROSTOL; NIZATIDINE; OXCARBAZEPINE; PHENYTOIN; RALITOLINE; RUFINAMIDE; UNINDEXED DRUG; VINPOCETINE; ZONISAMIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICONVULSANT ACTIVITY; ARTICLE; CONTROLLED STUDY; DISCRIMINANT ANALYSIS; DRUG SCREENING; MOUSE; NONHUMAN; ROTAROD TEST; STRUCTURE ACTIVITY RELATION; VALIDATION PROCESS;

ADMINISTRATION, ORAL; ALGORITHMS; ANIMALS; ANTICONVULSANTS; ARTIFICIAL INTELLIGENCE; COMPUTER SIMULATION; CONVULSANTS; DISCRIMINANT ANALYSIS; DITERPENES, ABIETANE; DRUG EVALUATION, PRECLINICAL; ELECTROSHOCK; INJECTIONS, INTRAPERITONEAL; LINEAR MODELS; MICE; PENTYLENETETRAZOLE; PHENANTHRENES; POSTURAL BALANCE; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 33847022957     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2006.12.098     Document Type: Article

References (27)

1. World Health Organization Fact sheet n° 265: Mental and neurological disorders. December 2001.
2. Bialer M., Johannessen S.I., Kupferberg H.J., Levy R.H., Loiseau P., and Perucca E. Epilepsy Res. 51 (2002) 31
3. Marrero-Ponce Y., Machado Tugores Y., Pereira D.N., Escario J.A., Barrio A.G., Nogal-Ruiz J.J., Ochoa C., Aran V.J., Martínez-Fernández A.R., García-Sánchez R.N., Montero-Torres A., Torrens F., and Meneses-Marcel A. Curr. Drug. Discov. Technol. 2 (2005) 245
4. Montero-Torres A., García-Sánchez R.M., Machado-Tugores Y., Nogal-Ruiz J.J., Martínez-Fernández A.R., Aran V.J., Ochoa C., Meneses-Marcel A., and Torrens F. Eur. J. Med. Chem. 41 (2006) 483
5. Marrero-Ponce Y., Cabrera-Pérez M.A., Romero-Zaldivar V., González-Díaz H., and Torrens F. J. Pharm. Pharm. Sci. 7 (2004) 186
6. García-García A., Gálvez J., de Julián-Ortiz J.V., García-Domenech R., Muñoz C., Guna1 R., and Borrás R. J. Antimicrob. Chemother. 53 (2004) 65
7. Julián-Ortiz J.V., Gálvez J., Muñoz Collado C., García-Domenech R., and Gimeno-Cardona C. J. Med. Chem. 42 (1999) 3308
8. Prieto J.J., Talevi A., and Bruno-Blanch L.E. Mol. Div. 10 (2006) 361
9. Talevi, A.; Bellera, C. L.; Castro, E. A.; Bruno-Blanch, L. E. Drugs Future. 2006, 31 (Suppl. A) Abstracts from the XIX International Symposium on Medicinal Chemistry, 188.
10. Talete srl DRAGON for Windows (Software for Molecular Descriptors Calculation) Version 4.0, 2003. www.talete.mi.it.
11. Raychaudhury C., Ray S.K., Ghosh J.J., Roy A.B., and Basak S.C. J. Comput. Chem. 5 (1984) 581
12. Magnuson D.R., Harriss V.K., and Basak S.C. Studies in physical and theoretical chemistry. In: King R.B. (Ed) (1983), Elsevier, Amsterdam 178
13. Geary R.C. Incorp. Statist. 5 (1954) 115
14. Gálvez J., García-Domenech R., Alapont de Gregorio C., De Julián-Ortiz J.V., and Popa L. J. Mol. Graph 14 (1996) 272
15. Yasri A., and Hartsough D. J. Chem. Inf. Comput. Sci. 41 (2001) 1218
16. Obniska J., Kaminski K., Zagorska A., Dzierzawska-Majewska A., and Karolak-Wojciechowska J. J. Fluorine Chem. 127 (2006) 417
17. Bialer M., Johannessen S.I., Kupferberg H.J., Levy R.H., Loiseau P., and Perucca E. Epilep. Res. 34 (1999) 1
18. De Sarro G., Ferreri G., Gareri P., Russo E., De Sarro A., Gitto R., and Chimirri A. Pharmacol. Biochem. Behav. 74 (2003) 595
19. Ferreri G., Chimirri A., Russo E., Gitto R., Gareri P., De Sarro A., and De Sarro G. Pharmacol. Biochem. Behav. 77 (2004) 85
20. Obniska J., Jurczyk S., Zejc A., Kamiñski K., Tatarczyñska E., and Stachowicz K. Pharmacol. Rep. 57 (2005) 170
21. Schenck H.A., Lenkowski P.W., Choudhury-Mukherjee I., Ko S., Stables J.P., Patel M.K., and Brown M.L. Bioorg. Med. Chem. 12 (2004) 979
22. Beguin C., LeTiran A., Stables J.P., Voyksnerc R.D., and Kohnd H. Bioorg. Med. Chem. 12 (2004) 3079
23. Kaymakci{dotless}oglu B.K., Rollas S., Korcegez E., and Ari{dotless}ci{dotless}oglu F. Eur. J. Pharm. Sci. 26 (2005) 97
24. The Merck Index, Encyclopedia of Chemicals, Drugs and Biologicals, 13th ed. Merck and Co. Withehouse Station, New Jersey, 2001.
25. Fernández M.A., Tornos M.P., García M.D., de las Heras B., Villar A.M., and Sáenz M.T. J. Pharm. Pharmacol. 53 (2001) 867
26. Liu T.P., Gao C.Z., and Feng L.Z.J. Tradit. Chin. Med. 5 (1985) 115
27. Stables J.P., Kupferberg H.J., and Gladding R. Molecular and cellular targets for antiepileptic drugs. In: Avanzini G., Regesta G., Tanganelli P., and Avoli M. (Eds) (1997), John Libbey, London 191